Deep brain stimulation of the subthalamic nucleus for a patient with drug resistant juvenile myoclonic epilepsy: 1 year follow-up.

Autor: Shan M; Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, P.R. China., Mao H; Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, P.R. China.; First Clinical Medical College, Anhui Medical University, Meishan Road 81, Hefei, 230032, P.R. China., Hu T; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China., Xie H; Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China., Ye L; Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, P.R. China., Cheng H; Department of Neurosurgery, the First Affiliated Hospital of Anhui Medical University, Jixi Road 218, Hefei, 230022, P.R. China. hongwei.cheng@ahmu.edu.cn.
Jazyk: angličtina
Zdroj: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology [Neurol Sci] 2024 Oct; Vol. 45 (10), pp. 4997-5002. Date of Electronic Publication: 2024 May 14.
DOI: 10.1007/s10072-024-07553-1
Abstrakt: Background: Drug-resistant juvenile myoclonic epilepsy (DR-JME) remains a significant challenge in neurology. Traditional management strategies often fail to achieve satisfactory control, necessitating innovative treatments.
Objective: This case report aims to evaluate the efficacy and safety of deep brain stimulation (DBS) targeting the subthalamic nucleus (STN-DBS) in a patient with DR-JME.
Methods: We describe the treatment of a patient with DR-JME using STN-DBS. The patient underwent implantation and received high-frequency stimulation (HFS) at the STN.
Results: One year post-implantation, the patient demonstrated a substantial reduction in motor seizure frequency by 87.5%, with improvements in quality of life and seizure severity by 52.0% and 46.7%, respectively. No adverse events were reported during the follow-up period.
Conclusions: This case represents the first report of favorable outcomes with STN-DBS in a patient with DR-JME, suggesting that long-term HFS of the STN may be a promising treatment option for patients suffering from this condition.
(© 2024. Fondazione Società Italiana di Neurologia.)
Databáze: MEDLINE
Externí odkaz: